Lantern Pharma Receives Certificate Of Patent From Japanese Patent Office (jpo) For Composition Of Matter Covering Drug Candidate Lp-284

Lantern Pharma Inc. has received a Certificate of Patent from the Japan Patent Office for their drug candidate LP-284, which uses their proprietary RADR® AI and machine learning platform. This patent strengthens their intellectual property portfolio and supports the use of AI in developing novel cancer therapies.